๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics of ethopropazine in the rat after oral and intravenous administration

โœ Scribed by Mojdeh Maboudian-Esfahani; Dion R. Brocks


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
115 KB
Volume
20
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


The pharmacokinetics of the anticholinergic drug ethopropazine (ET) have been studied in the rat after intravenous (i.v.) and oral administration. After i.v. doses of 5 and 10 mg/kg ET HCl, mean +/- S.D. plasma AUC were 9836 +/- 2129 (n = 4 rats) and 13096 +/- 4186 ng h/mL (n = 5 rats), respectively. The t1/2 after 5 and 10 mg/kg i.v. doses were 17.9 +/- 3.3 and 20.9 +/- 6.0 h, respectively. The Cl and V(dss) after 5 mg/kg i.v. doses were 0.48 +/- 0.10 L/h/kg and 7.1 +/- 2.3 L/kg, respectively. Statistically significant differences were present between the 5 and 10 mg/kg dose levels in Cl and V(dss). Oral administration of 50 mg/kg ET HCl (n = 5 rats) yielded mean AUC of 2685 +/- 336 ng h/mL. Mean plasma C(max), t(max) and t1/2 after oral doses were 236 +/- 99 ng/mL, 2.2 +/- 1.4 h and 26.1 +/- 5.4 h, respectively. Less than 1% of the dose was recovered unchanged in urine and bile. Ethopropazine is extensively distributed in the rat, and has relatively slow Cl in relation to hepatic blood flow in the rat. The drug appears to be extensively metabolized in the rat, and nonlinearity is present between the 5 and the 10 mg/kg i.v. doses. The drug displayed poor bioavailability (< 5%) after oral administration.


๐Ÿ“œ SIMILAR VOLUMES


PHARMACOKINETICS OF SUPEROXIDE DISMUTASE
โœ C. Regnault; M. Soursac; M. Roch-Arveiller; E. Postaire; G. Hazebroucq ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 479 KB ๐Ÿ‘ 1 views

The kinetic behaviour of bovine erythrocyte Cu-Zn SOD was investigated in Sprague Dawley male rats after subcutaneous and oral administrations of doses ranging from 0.5 to 20mgkg-I. Studies have been carried out with SOD and SOD encapsulated into liposomes containing or not containing ceramides. The

PHARMACOKINETICS OF THE ENANTIOMERS OF V
โœ M. MASOOD BHATTI; ROBERT T. FOSTER ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 111 KB ๐Ÿ‘ 1 views

Verapamil is a chiral calcium channel blocking drug which is useful clinically as the racemate in treating hypertension and arrhythmia. The published pharmacokinetic data for verapamil enantiomers in the rat model are limited. Utilizing a stereospeciยฎc highperformance liquid chromatographic (HPLC) a

Pharmacokinetics of single oral and mult
โœ S. Abolfazl Mostafavi; Robert T. Foster ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 138 KB ๐Ÿ‘ 2 views

Acebutolol (AC), is a chiral, i-adrenergic blocking agent which possesses partial agonist activity and is metabolized to an equipotent chiral metabolite, diacetolol (DC). The enantiomeric disposition of AC is reported following racemic administration as a single oral (p.o., 50 mg kg -1 ) or as a mul

Pharmacokinetic and pharmacodynamic chan
โœ Joo H. Park; Woo I. Lee; Woo H. Yoon; Young-D. Park; Jung-S. Lee; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 163 KB ๐Ÿ‘ 1 views

Because some physiological changes occurring in diabetes mellitus patients could alter the pharmacokinetics and pharmacodynamics of the drugs to treat the disease, the pharmacokinetics and pharmacodynamics of furosemide were investigated after intravenous (i.v.) and oral administration of the drug (

Pharmacokinetics of fenvalerate after in
โœ Danielson, Terry J.; Golsteyn, Lorraine R.; Elder, James L. ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 475 KB ๐Ÿ‘ 1 views

The pharmacokinetics of total radioactivity and of intact fenvalerate were determined in sheep treated intravenously with radiolabelled or nonradiolabelled fenvalerate. Mean residence times (MRT) of total radioactivity and intact fenvalerate in plasma were 910 (f 75) and 39 ( f 3) min, while harmoni

Pharmacokinetics of deramciclane in dogs
โœ Harri Kanerva; Hannele Huuskonen; Anneli Alhonen-Raatesalmi; Timo Nevalainen; Ar ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 204 KB ๐Ÿ‘ 2 views

The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der